Arvinas Announces Key Data Presentations on Vepdegestrant
Arvinas, Inc. (NASDAQ: ARVN), a pioneer in biotechnology focused on targeted protein degradation, is set to showcase its innovative treatment, vepdegestrant (ARV-471), at a major symposium. The company's presence at the upcoming San Antonio Breast Cancer Symposium (SABCS) promises to deliver valuable insights into its clinical development program.
Overview of Vepdegestrant
Vepdegestrant stands out as a promising investigational agent designed to target estrogen receptors effectively. Developed in collaboration with Pfizer Inc. (NYSE: PFE), this innovative PROTAC (Proteolysis Targeting Chimera) estrogen receptor degrader aims to improve treatment options for patients facing estrogen receptor positive (ER+) and HER2-negative advanced breast cancer, particularly those with ESR1 mutations. This potential breakthrough therapy is currently evaluated as a monotherapy and in combination with other agents.
Upcoming Presentations at SABCS
The company will feature several key presentations at SABCS, scheduled from December 9 to December 12. Each of these presentations will provide a unique perspective on the application of vepdegestrant in treating advanced breast cancer.
Key Presentation Details
The details of the presentations are as follows:
- Title: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant versus fulvestrant in ER+/HER2- advanced breast cancer
Presenting Author: Erika P. Hamilton
Presentation Number: PD10-03
Session: Poster Spotlight 10
Date: December 12 - Title: Circulating tumor DNA biomarker analyses of a phase 1/2 study of vepdegestrant in ER+/HER2- advanced breast cancer
Presenting Author: Seth A. Wander
Presentation Number: PS2-07-24
Session: Poster Session 2
Date: December 10 - Title: Real-world prevalence of ESR1 mutations in patients with metastatic breast cancer
Presenting Author: David Chandiwana
Presentation Number: PS1-11-09
Session: Poster Session 1
Date: December 10 - Title: I-SPY2 Endocrine Optimization Pilot study evaluating vepdegestrant in combination with letrozole or abemaciclib
Presenting Author: Jo Chien
Presentation Number: PD10-02
Session: Poster Spotlight 10
Date: December 12 - Title: Phase 1/2 trial evaluating safety and efficacy of KAT6 inhibitor with vepdegestrant
Presenting Author: Fengting Yan
Presentation Number: PS5-09-30
Session: Poster Session 5
Date: December 12
Significance of the Research
The research and presentations at SABCS represent a significant step forward for Arvinas, demonstrating the potential of vepdegestrant to enhance treatment options for patients suffering from advanced breast cancer. With the support of ongoing studies, these presentations underscore Arvinas' commitment to addressing critical unmet medical needs in oncology.
The Future of Vepdegestrant
As part of its development program, Arvinas has filed a New Drug Application (NDA) with the U.S. FDA for vepdegestrant, which has been assigned a PDUFA date for potential approval. This progress has been accompanied by the FDA granting Fast Track designation for vepdegestrant, highlighting its importance in treating a significant patient population struggling with advanced cancer.
About Arvinas and Its Mission
Arvinas, Inc. (NASDAQ: ARVN) is committed to creating innovative therapies that harness the body’s natural protein disposal system for the treatment of various diseases. By utilizing its cutting-edge PROTAC platform, the company aims to make groundbreaking advancements in how proteins that contribute to disease are targeted and degraded. This forward-thinking approach positions Arvinas at the forefront of biotechnology as it continues to progress with multiple investigational drugs.
Frequently Asked Questions
What is vepdegestrant?
Vepdegestrant is an investigational PROTAC estrogen receptor degrader being developed for advanced breast cancer treatment.
When will the SABCS take place?
The San Antonio Breast Cancer Symposium will occur from December 9 to December 12.
Who is collaborating with Arvinas on vepdegestrant?
Arvinas is collaborating with Pfizer Inc. for the co-development and commercialization of vepdegestrant.
What is the goal of the upcoming presentations?
The presentations aim to share new clinical data on vepdegestrant's effectiveness and potential as a treatment for advanced breast cancer.
What is the current status of the vepdegestrant application to the FDA?
The FDA is reviewing the New Drug Application for vepdegestrant, with a decision expected by the assigned PDUFA date.
